ReviewHandbook of experimental pharmacology2026
Role of Innate Immune Receptors in Cardiac Damage Linked to Metabolic Disorders.
Review in Handbook of experimental pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This chapter underscores the pivotal role of immune receptors, particularly Toll-like receptors (TLRs) and NOD-like receptors (NLRs), in the intricate interplay between metabolic diseases and their associated cardiovascular comorbidities. Their involvement extends beyond mere initiation, profoundly influencing the progression of these complex conditions. The recognition of TLRs and NLRs as promising therapeutic targets is a significant advancement, offering potential avenues for intervention in both metabolic disorders and their cardiovascular sequels.The significance of these pattern recognition receptors (PRRs) lies in their capacity to orchestrate inflammatory responses, a critical factor in the pathogenesis of metabolic diseases. Dysregulation of these pathways contributes to chronic, low-grade inflammation, a hallmark of conditions such as obesity and type 2 diabetes. This persistent inflammation, in turn, fuels the development of cardiovascular complications such as atherosclerosis, hypertension, and heart failure.Targeting TLRs and NLRs presents a strategic approach to modulate these inflammatory cascades. By selectively inhibiting or modulating the activity of these receptors, it may be possible to mitigate the detrimental effects of chronic inflammation and prevent or delay the onset of associated comorbidities. However, this approach requires a thorough understanding of the specific TLR and NLR subtypes involved in various disease processes, as well as the intricate signaling pathways they activate.Furthermore, the development of therapeutic strategies targeting PRRs must consider the potential for off-target effects and the need for personalized medicine. Given the diverse expression patterns and functional roles of TLRs and NLRs across various cell types and tissues, a tailored approach is essential to maximize efficacy and minimize adverse effects. Consequently, ongoing research is focused on identifying specific ligands and inhibitors that can selectively target these receptors, paving the way for novel therapeutic interventions.
Indexed as
Identifiers
41760932What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.